Vivera Pharmaceuticals

Vivera Pharmaceuticals is a privately-held, vertically integrated biopharma and medtech company founded in 2018. Its core strategy revolves around developing and commercializing patented drug delivery and medical device technologies, primarily targeting the opioid epidemic and pain management with non-addictive alternatives. The company appears to be in a pre-revenue or early-revenue stage, focusing on building its intellectual property portfolio, securing global patents, and advancing its technologies through regulatory pathways. Recent activities highlight significant legal actions and the recruitment of former FDA personnel to bolster regulatory strategy.

Patented drug delivery and medical device technologies including the TABMELT sublingual delivery system (exclusively licensed), the ZICOH dose-controlled electronic dispensing device, the MDZone telemedicine station, and a speech fluency evaluation device.

Vivera competes in crowded spaces: drug delivery (with large pharma and specialty firms), smart medical devices (with digital health companies), and telemedicine. Success depends on demonstrating superior efficacy, usability, and securing strong IP protection against established and emerging competitors.